- 同
- glucagon-like peptide-1
WordNet
- of or related to the anus; "anal thermometer"
- a stage in psychosexual development when the childs interest is concentrated on the anal region; fixation at this stage is said to result in orderliness, meanness, stubbornness, compulsiveness, etc. (同)anal retentive
- the 7th letter of the Roman alphabet (同)g
PrepTutorEJDIC
- 肛門(こうもん)(anus)の
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/03 05:34:20」(JST)
[Wiki en表示]
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.[1] One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]
There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas.[3]
Approved GLP-1 agonists:
- exenatide (Byetta/Bydureon), approved in 2005/2012
- liraglutide (Victoza, Saxenda), approved 2010[4]
- lixisenatide (Lyxumia), approved in EU 2013[5]
- albiglutide (Tanzeum), approved in 2014 by GSK[6]
- dulaglutide (Trulicity), approved in 2014 - manufactured by Eli Lily K[7]
Under investigation: [1]
- taspoglutide, phase III halted Sept 2010,
These agents work in the same pathway as DPP-4 inhibitors but are generally considered more potent.[8]
References
- ^ a b Baggio LL (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". Medscape Diabetes & Endocrinology.
- ^ "Standards of medical care in diabetes--2012". Diabetes Care. 35 Suppl 1: S11–63. 2012. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
- ^ Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, Braun B, Herwaldt L (2013). "Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis". BMJ 346: f2743. doi:10.1136/bmj.f2743. PMC 3681273. PMID 23766464.
- ^ "FDA Approves New Treatment for Type 2 Diabetes".
- ^ "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA".
- ^ "FDA Approves Weekly Injectable Diabetes Drug: Albiglutide".
- ^ "FDA Approves Weekly Injectable Diabetes Drug: Dulaglutide".
- ^ "GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes".
|
Oral anti-diabetic drugs and Insulin analogs (A10)
|
|
| Insulin |
| Sensitizers |
| Biguanides |
- Metformin#
- Buformin‡
- Phenformin‡
|
|
| TZDs/"glitazones" (PPAR) |
- Pioglitazone
- Rivoglitazone†
- Rosiglitazone
- Troglitazone‡
|
|
| Dual PPAR agonists |
- Aleglitazar†
- Muraglitazar§
- Saroglitazar
- Tesaglitazar§
|
|
|
| Secretagogues |
| K+ ATP |
| Sulfonylureas |
- 1st generation: Acetohexamide
- Carbutamide
- Chlorpropamide
- Metahexamide
- Tolbutamide
- Tolazamide
- 2nd generation: Glibenclamide (Glyburide)#
- Glibornuride
- Glipizide
- Gliquidone
- Glisoxepide
- Glyclopyramide
- Glimepiride
- Gliclazide
|
|
| Meglitinides/"glinides" |
- Nateglinide
- Repaglinide
- Mitiglinide
|
|
|
| GLP-1 agonists |
- Exenatide
- Liraglutide
- Taspoglutide†
- Albiglutide†
- Lixisenatide
- Dulaglutide
- Semaglutide
|
|
| DPP-4 inhibitors |
- Alogliptin
- Anagliptin
- Gemigliptin
- Linagliptin
- Omarigliptin
- Saxagliptin
- Sitagliptin
- Teneligliptin
- Vildagliptin
|
|
| GPR40 Free fatty acid receptor 1 |
|
|
|
| Analogs/other insulins |
- fast-acting (Insulin lispro
- Insulin aspart
- Insulin glulisine)
- short-acting (Regular insulin)
- long-acting (Insulin glargine
- Insulin detemir
- NPH insulin)
- ultra-long-acting (Insulin degludec†)
- inhalable Exubera
- Afrezza
|
|
|
| Other |
| Alpha-glucosidase inhibitors |
- Acarbose
- Miglitol
- Voglibose
|
|
| Amylin analog |
|
|
| Gliflozins |
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Remogliflozin§
- Sergliflozin§
- Tofogliflozin†
|
|
| Other |
- Bromocriptine
- Benfluorex‡
- Tolrestat‡
|
|
|
-
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
Index of hormones
|
|
| Description |
- Glands
- Hormones
- thyroid
- mineralocorticoids
- Physiology
- Development
|
|
| Disease |
- Diabetes
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
|
|
| Treatment |
- Procedures
- Drugs
- calcium balance
- corticosteroids
- oral hypoglycemics
- pituitary and hypothalamic
- thyroid
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with (68)Ga-DOTA-octreotide: A potential PET tracer for beta cell mass measurement.
- Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, Cui Y, Kataoka Y, Senda M, Watanabe Y.SourceDivision of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Division of Molecular Imaging, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.
- Biochemical and biophysical research communications.Biochem Biophys Res Commun.2013 Dec 6;442(1-2):79-84. doi: 10.1016/j.bbrc.2013.11.001. Epub 2013 Nov 9.
- Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia, and the loss or dysfunction of pancreatic beta cells has been reported before the appearance of clinical symptoms and hyperglycemia. To evaluate beta cell mass (BCM) for improving the detection and treatment of DM at earl
- PMID 24220338
- A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
- Bianchi E, Carrington PE, Ingallinella P, Finotto M, Santoprete A, Petrov A, Eiermann G, Kosinski J, Marsh DJ, Pocai A, SinhaRoy R, Pessi A.SourceIRBM P. Angeletti, 00040 Pomezia, Rome, Italy.
- Bioorganic & medicinal chemistry.Bioorg Med Chem.2013 Nov 15;21(22):7064-73. doi: 10.1016/j.bmc.2013.09.016. Epub 2013 Sep 19.
- Peptide agonists of the glucagon-like peptide 1 (GLP-1) receptor (GLP1R) are rapidly gaining favor as antidiabetic agents, since in addition to increasing glucose-dependent insulin secretion, they also cause weight loss. Oxyntomodulin (OXM), a natural peptide with sequence homology to both glucagon
- PMID 24094437
- PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
- Nakamura T, Ito T, Uchida M, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Jensen RT, Takayanagi R.Source1] Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan [2] Department of Cell Biology Section, NIDDK, National Institutes of Health, Bethesda, MD, USA.
- Laboratory investigation; a journal of technical methods and pathology.Lab Invest.2013 Nov 11. doi: 10.1038/labinvest.2013.133. [Epub ahead of print]
- There is increasing concern about the development of pancreatitis in patients with diabetes mellitus who received long-term glucagon-like peptide-1 (GLP-1) analog treatment. Its pathogenesis is unknown. The effects of GLP-1 agonists on pancreatic endocrine cells are well studied; however, there is l
- PMID 24217090
Japanese Journal
- インスリンからGLP-1アナログ(リラグルチド)へ切り替えた2型糖尿病透析患者の記述疫学的検討
- Normalization of fasting hyperglycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabetes mellitus
- IIZUKA Katsumi,TOMITA Reiko,SUWA Tetsuya,HORIKAWA Yukio,TAKEDA Jun
- Diabetology international 3(1), 61-64, 2013-03-01
- NAID 10030925908
- Normalization of fasting hyperglycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabetes mellitus
- Iizuka Katsumi,Tomita Reiko,Suwa Tetsuya [他]
- Diabetology international 3(1), 61-64, 2012
- NAID 40019209011
Related Links
- Glucagon-like peptide-1 agonist. From Wikipedia, the free encyclopedia. Jump to: navigation, search. Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes. One of their advantages over ...
- GLP-1. 出典: フリー百科事典『ウィキペディア（Wikipedia）』. 移動: 案内、 検索 ... GLP- 1とは、グルカゴン様ペプチド-1 (Glucagon-like peptide-1) の略。1983年に同定された 消化管ホルモンで、消化管に入った炭水化物 ... GLP-1アナログ製剤; リキシセナチド .
★リンクテーブル★
[★]
- 関
- analogue、derivate、derivative、relative
linux
| 1
|
YEARLY
|
年別レポート
|
|
| Q
|
QUARTERLY
|
4半期別レポート
|
|
| m
|
MONTHLY
|
月別レポート
|
|
| W
|
WEEKLY
|
週別レポート
|
ON
|
| D
|
DAILYREP
|
日別レポート
|
ON
|
| d
|
DAILYSUM
|
曜日別集計
|
|
| H
|
HOURLYREP
|
時間別レポート
|
ON
|
| h
|
HOURLYSUM
|
時間別集計
|
ON
|
| w
|
WEEKHOUR
|
曜日別時間集計
|
|
| 4
|
QUARTERREP
|
15分間隔レポート
|
ON
|
| 6
|
QUARTERSUM
|
15分間隔集計
|
ON
|
| 5
|
FIVEREP
|
5分間隔レポート
|
|
| 7
|
FIVESUM
|
5分間隔集計
|
|
| S
|
HOST
|
ホストレポート
|
ON
|
| l
|
REDIRHOST
|
ホストリダイレクションレポート
|
ON
|
| L
|
FAILHOST
|
ホスト不成功レポート
|
ON
|
| Z
|
ORGANISATION
|
組織レポート
|
ON
|
| o
|
DOMAIN
|
ドメインレポート
|
ON
|
| r
|
REQUEST
|
リクエストレポート
|
ON
|
| i
|
DIRECTORY
|
ディレクトリレポート
|
ON
|
| t
|
FILETYPE
|
ファイル種類別レポート
|
ON
|
| z
|
SIZE
|
ファイルサイズレポート
|
ON
|
| P
|
PROCTIME
|
処理時間レポート
|
ON
|
| E
|
REDIR
|
リダイレクトレポート
|
ON
|
| I
|
FAILURE
|
不成功レポート
|
ON
|
| f
|
REFERRER
|
リンク元レポート
|
ON
|
| s
|
REFSITE
|
リンク元サイトレポート
|
ON
|
| N
|
SEARCHQUERY
|
検索語句レポート
|
ON
|
| n
|
SEARCHWORD
|
検索語レポート
|
ON
|
| Y
|
INTSEARCHQUERY
|
内部検索語句レポート
|
ON
|
| y
|
INTSEARCHWORD
|
内部検索単語レポート
|
ON
|
| k
|
REDIRREF
|
リダイレクトされたリンク元URLレポート
|
ON
|
| K
|
FAILREF
|
不成功リンク元レポート
|
ON
|
| B
|
FULLBROWSER
|
ブラウザーレポート
|
ON
|
| b
|
BROWSER
|
ブラウザーの概要
|
ON
|
| p
|
OSREP
|
OSレポート
|
ON
|
| v
|
VHOST
|
仮想ホストレポート
|
ON
|
| R
|
REDIRVHOST
|
仮想ホストリダイレクションレポート
|
ON
|
| M
|
FAILVHOST
|
仮想ホスト不成功レポート
|
ON
|
| u
|
USER
|
ユーザレポート
|
ON
|
| j
|
REDIRUSER
|
ユーザリダイレクションレポート
|
ON
|
| J
|
FAILUSER
|
不成功ユーザレポート
|
ON
|
| c
|
STATUS
|
状態コードレポート
|
ON
|
[★]
- 関
- glucagon-like peptide、good laboratory practice
[★]
- 関
- analyse、analyses、analysis、analytical、analyze、ani、anus、assay、dissect
[★]